Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06462365 · ClinicalTrials.gov registry record · Phase 1
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
A Phase 1 study of Myelodysplastic Syndromes and Hematologic Malignancy, sponsored by Tr1X.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 5
- Study locations
NCT06462365: Recruiting Phase 1 study of Myelodysplastic Syndromes and Hematologic Malignancy, sponsored by Tr1X.
NCT06462365 is a Phase 1 study of Myelodysplastic Syndromes and Hematologic Malignancy that is actively recruiting participants, run by Tr1X. The registered enrollment target is 36 participants, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (87% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06462365, a Phase 1 study of Myelodysplastic Syndromes and Hematologic Malignancy, is actively recruiting participants, sponsored by Tr1X.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell transplantation (HSCT). It is anticipated that up to 36 Subjects will be enrolled during a 18-24 month enrollment period. TRX-103 will be infused one time post HSCT.
Conditions Studied
Interventions
- BIOLOGICAL TRX103
Study Locations (5)
California
- City of Hope - Duarte
Massachusetts
- Dana-Farber Cancer Institute - Boston
Minnesota
- University of Minnesota - Minneapolis
New York
- Memorial Sloan Kettering Cancer Center - New York
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2024-04-08 |
| Est. Completion | 2027-04-15 |
| Phase | Phase 1 |
What NCT06462365 shows while recruiting
NCT06462365 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (87% lower).
The record links to 10 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 1 intervention - of which TRX103 is the first listed.
NCT06462365 lists 5 locations in 5 states (California, Massachusetts, Minnesota).
Frequently Asked Questions
What is clinical trial NCT06462365 about?
NCT06462365 is a clinical study titled "Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)". The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell transplantation (HSCT). It is anticipated that up to 36 Subjects will be...
What is the current status of trial NCT06462365?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2024-04-08. Estimated completion is 2027-04-15.
What conditions does trial NCT06462365 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes, Hematologic Malignancy, Acute Myeloid Leukemia in Remission, Hematopoietic Stem Cell Transplant, GvHD.
What interventions are being tested in trial NCT06462365?
The interventions under investigation include: TRX103 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06462365?
This trial is sponsored by Tr1X, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06462365 being conducted?
This trial has 5 study locations across California, Massachusetts, Minnesota, New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06462365's enrollment target sits among peer trials
36 110th of 173 higher than 62 of 173 other Myelodysplastic Syndromes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelodysplastic Syndromes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
RECRUITING · Phase 1
-
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
RECRUITING · Phase 1
-
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
RECRUITING · Phase 1
-
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI